Cargando…

Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1

SUMMARY: Tyrosinaemia type 1 (TT1) is a rare inherited disorder of amino acid metabolism typically presenting with liver failure and renal tubular dysfunction. We describe three individuals with TT1 and transient hyperinsulinaemic hypoglycaemia (HH). Two siblings with TT1 and acute liver dysfunction...

Descripción completa

Detalles Bibliográficos
Autores principales: Sotiridou, Ellada, Hoermann, Henrike, Aftab, Sommayya, Dastamani, Antonia, Thimm, Eva, Doodson, Louise, Batzios, Spyros, Kummer, Sebastian, Shah, Pratik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849471/
https://www.ncbi.nlm.nih.gov/pubmed/33431709
http://dx.doi.org/10.1530/EDM-20-0174
_version_ 1783645308955131904
author Sotiridou, Ellada
Hoermann, Henrike
Aftab, Sommayya
Dastamani, Antonia
Thimm, Eva
Doodson, Louise
Batzios, Spyros
Kummer, Sebastian
Shah, Pratik
author_facet Sotiridou, Ellada
Hoermann, Henrike
Aftab, Sommayya
Dastamani, Antonia
Thimm, Eva
Doodson, Louise
Batzios, Spyros
Kummer, Sebastian
Shah, Pratik
author_sort Sotiridou, Ellada
collection PubMed
description SUMMARY: Tyrosinaemia type 1 (TT1) is a rare inherited disorder of amino acid metabolism typically presenting with liver failure and renal tubular dysfunction. We describe three individuals with TT1 and transient hyperinsulinaemic hypoglycaemia (HH). Two siblings with TT1 and acute liver dysfunction were diagnosed with hyperinsulinaemic hypoglycaemia in the neonatal period. Both siblings were successfully treated with diazoxide/chlorthiazide and treatment was gradually weaned and stopped after 8 and 6 months of age respectively. The third patient presented with a neonatal liver failure with mild cholestasis, coagulopathy, fundus haemorrhages, vitamin A and E deficiency and hyperinsulinaemic hypoglycaemia. He maintained euglycaemia on high dose diazoxide (5–12 mg/kg/day) but developed pulmonary hypertension at 12 weeks of age. After discontinuation of diazoxide, he continued maintaining his blood glucose (BG) within the normal range. Although histological abnormalities of the pancreas including beta-cell hyperplasia are well documented, the exact mechanism of excessive insulin secretion in TT1 is not well understood. It may be related to the accumulation of toxic metabolites in the target organs including pancreas. Therefore, in patients with TT1 and persistent hypoglycaemia beyond the recovery of the acute liver failure, it is important to exclude hyperinsulinism which is usually transient and can be successfully treated with diazoxide and chlorothiazide. Further studies are required to determine which factors contribute to excessive insulin secretion in patients with TT1. LEARNING POINTS: Every child with TT1 should be monitored for signs and symptoms of hypoglycaemia and screened for HH at the time of real hypoglycaemia. If hypoglycaemic episodes persist even after improvement of liver function, hyperinsulinism should be suspected. Treatment with diazoxide is effective, however, children need to be monitored closely for possible side effects. The pathophysiological mechanism of hyperinsulinism in children with TT1 is not elucidated yet and further studies are required to determine which factors contribute to excessive insulin secretion in patients with TT1.
format Online
Article
Text
id pubmed-7849471
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-78494712021-02-03 Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1 Sotiridou, Ellada Hoermann, Henrike Aftab, Sommayya Dastamani, Antonia Thimm, Eva Doodson, Louise Batzios, Spyros Kummer, Sebastian Shah, Pratik Endocrinol Diabetes Metab Case Rep Unique/Unexpected Symptoms or Presentations of a Disease SUMMARY: Tyrosinaemia type 1 (TT1) is a rare inherited disorder of amino acid metabolism typically presenting with liver failure and renal tubular dysfunction. We describe three individuals with TT1 and transient hyperinsulinaemic hypoglycaemia (HH). Two siblings with TT1 and acute liver dysfunction were diagnosed with hyperinsulinaemic hypoglycaemia in the neonatal period. Both siblings were successfully treated with diazoxide/chlorthiazide and treatment was gradually weaned and stopped after 8 and 6 months of age respectively. The third patient presented with a neonatal liver failure with mild cholestasis, coagulopathy, fundus haemorrhages, vitamin A and E deficiency and hyperinsulinaemic hypoglycaemia. He maintained euglycaemia on high dose diazoxide (5–12 mg/kg/day) but developed pulmonary hypertension at 12 weeks of age. After discontinuation of diazoxide, he continued maintaining his blood glucose (BG) within the normal range. Although histological abnormalities of the pancreas including beta-cell hyperplasia are well documented, the exact mechanism of excessive insulin secretion in TT1 is not well understood. It may be related to the accumulation of toxic metabolites in the target organs including pancreas. Therefore, in patients with TT1 and persistent hypoglycaemia beyond the recovery of the acute liver failure, it is important to exclude hyperinsulinism which is usually transient and can be successfully treated with diazoxide and chlorothiazide. Further studies are required to determine which factors contribute to excessive insulin secretion in patients with TT1. LEARNING POINTS: Every child with TT1 should be monitored for signs and symptoms of hypoglycaemia and screened for HH at the time of real hypoglycaemia. If hypoglycaemic episodes persist even after improvement of liver function, hyperinsulinism should be suspected. Treatment with diazoxide is effective, however, children need to be monitored closely for possible side effects. The pathophysiological mechanism of hyperinsulinism in children with TT1 is not elucidated yet and further studies are required to determine which factors contribute to excessive insulin secretion in patients with TT1. Bioscientifica Ltd 2021-01-11 /pmc/articles/PMC7849471/ /pubmed/33431709 http://dx.doi.org/10.1530/EDM-20-0174 Text en © 2021 The authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (http://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Unique/Unexpected Symptoms or Presentations of a Disease
Sotiridou, Ellada
Hoermann, Henrike
Aftab, Sommayya
Dastamani, Antonia
Thimm, Eva
Doodson, Louise
Batzios, Spyros
Kummer, Sebastian
Shah, Pratik
Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1
title Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1
title_full Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1
title_fullStr Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1
title_full_unstemmed Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1
title_short Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1
title_sort diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1
topic Unique/Unexpected Symptoms or Presentations of a Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849471/
https://www.ncbi.nlm.nih.gov/pubmed/33431709
http://dx.doi.org/10.1530/EDM-20-0174
work_keys_str_mv AT sotiridouellada diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1
AT hoermannhenrike diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1
AT aftabsommayya diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1
AT dastamaniantonia diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1
AT thimmeva diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1
AT doodsonlouise diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1
AT batziosspyros diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1
AT kummersebastian diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1
AT shahpratik diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1